Zobrazeno 1 - 10
of 37
pro vyhledávání: '"L. S. Rosen"'
Autor:
L. S. Rosen
Publikováno v:
Canadian Accounting Perspectives. 5:257-286
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c238991e7b1cc5f59b6c937a8f482ec
https://doi.org/10.1506/0frf-356q-bgqm-pff7
https://doi.org/10.1506/0frf-356q-bgqm-pff7
Publikováno v:
Journal of clinical pharmacy and therapeutics. 39(6)
Summary What is known and objective Navitoclax, a first-in-class small molecule Bcl-2 family inhibitor, is metabolized in vitro by the hepatic microsomal cytochrome P450 (CYP) enzymes CYP3A4. Drugs that affect CYP3A4 may therefore have an impact on t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ad1418eb0429e463077c1f7c91f5547
https://pubmed.ncbi.nlm.nih.gov/25047139
https://pubmed.ncbi.nlm.nih.gov/25047139
Autor:
C Thomas, Stuart J. Youngner, M. Abecassis, L Williams, Charles Miller, C R Atkins, John M. Davis, D Moss, L S Rosen, David M. Briscoe, Robert M. Arnold, Patricia L. Adams, Robert S. Gaston, Cheryl L. Jacobs, Robert J. Corry, Aaron Spital, Francis L. Delmonico, William M. Bennett, Laura A. Siminoff, Mark L. Barr, Jeffrey P. Kahn, Mark Raymond Adams, William E. Harmon, Margaret J. Bia, F H Wright, J M Newmann, James Burdick, L S Tyler, A. B. Leichtman, Vaughn A. Starnes
Publikováno v:
JAMA: The Journal of the American Medical Association. 284:2919-2926
Objective To recommend practice guidelines for transplant physicians, primary care providers, health care planners, and all those who are concerned about the well-being of the live organ donor. Participants An executive group representing the Nationa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef525446ecd63b015a984fb6e77740d4
https://doi.org/10.1001/jama.284.22.2919
https://doi.org/10.1001/jama.284.22.2919
Publikováno v:
Anticancer research. 31(2)
The purpose of this study was to investigate the effect of gimeracil (CDHP), a reversible dihydropyrimidine dehydrogenase (DPD) inhibitor, on the pharmacokinetics of 5-fluorouracil (5-FU) and other related metabolites by comparing the pharmacokinetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::674f6b2a68c4e512147eecceda93e176
https://pubmed.ncbi.nlm.nih.gov/21378348
https://pubmed.ncbi.nlm.nih.gov/21378348
Autor:
Grant A. McArthur, George Wilding, L. S. Rosen, Georgia Kollia, Christopher Sweeney, S. Galbraith, D. Feltquate, D. S. A. Nuyten, Derek J. Jonker, Linda M. Velasquez, Michael B. Sawyer, Samira Syed, F. de Braud, J Kantor, Glenwood D. Goss, O. Mokliatchouk, G.J.S. Rustin, Gordon C Jayson
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 22(6)
Background: This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors. Patients and methods: Ninety patients enrolled in this two-part, phase I open-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62e8665ebdca934dca8d74efaf8a097e
https://pubmed.ncbi.nlm.nih.gov/21131369
https://pubmed.ncbi.nlm.nih.gov/21131369
Autor:
L S, Rosen
Publikováno v:
Cancer journal (Sudbury, Mass.). 7
Angiogenesis plays a central role in a variety of physiologic and pathologic disease states. Because the growth and metastasis of malignant neoplasms require the presence of an adequate blood supply, pharmacologic inhibition of tumor-induced angiogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::844b060ad734b713c0fe2e5a364386b3
https://pubmed.ncbi.nlm.nih.gov/11779082
https://pubmed.ncbi.nlm.nih.gov/11779082
Autor:
L S, Rosen, D, Gordon, M, Kaminski, A, Howell, A, Belch, J, Mackey, J, Apffelstaedt, M, Hussein, R E, Coleman, D J, Reitsma, J J, Seaman, B L, Chen, Y, Ambros
Publikováno v:
Cancer journal (Sudbury, Mass.). 7(5)
Zoledronic acid, a new and more potent bisphosphonate, was compared with pamidronate, the current standard treatment for patients with osteolytic or mixed bone metastases/lesions.A total of 1,648 patients with either Durie-Salmon stage III multiple m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bec4473561928af13eb5046d301f9d99
https://pubmed.ncbi.nlm.nih.gov/12184414
https://pubmed.ncbi.nlm.nih.gov/12184414
Autor:
J R, Berenson, R A, Vescio, L S, Rosen, J M, VonTeichert, M, Woo, R, Swift, A, Savage, E, Givant, M, Hupkes, H, Harvey, A, Lipton
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(3)
Bisphosphonates are potent inhibitors of bone resorption and provide a therapeutic benefit for patients with bone metastases. Zoledronic acid is a highly potent, nitrogen-containing bisphosphonate. In the present trial, we assessed the safety and tol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3c5fa80e2e9bb1b57f732e6562d1c71b
https://pubmed.ncbi.nlm.nih.gov/11297237
https://pubmed.ncbi.nlm.nih.gov/11297237
Autor:
J R, Berenson, L S, Rosen, A, Howell, L, Porter, R E, Coleman, W, Morley, R, Dreicer, S A, Kuross, A, Lipton, J J, Seaman
Publikováno v:
Cancer. 91(7)
This study evaluated the dose-response relation for zoledronic acid, a new generation high potency bisphosphonate, given as a 5-minute infusion in patients with malignant osteolytic disease.Two-hundred eighty patients with osteolytic lesions due to m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dd11351eb2331c081c01d7ab52f072ae
https://pubmed.ncbi.nlm.nih.gov/11283917
https://pubmed.ncbi.nlm.nih.gov/11283917